Sierra Oncology's bone marrow cancer drug meets study main goal
Yahoo! Finance
Sierra Oncology Inc said on Tuesday its experimental drug for anemic patients with a type of bone marrow cancer met the main goal of reducing disease symptoms and also cut patients' dependence on blood transfusions, in a late-stage trial. The company acquired https://www.prnewswire.com/news-releases/sierra-oncology-acquires-momelotinib-an-investigational-janus-kinase-jak-12-and-activin-receptor-type-1-acvr1-inhibitor-for-myelofibrosis-from-gilead-sciences-300700644.html the drug, momelotinib, f...
Continue Reading